Plataforma BIOBADASER III

Congresos

• What Is the Impact of Prior TNF Inhibitor Treatment on the Time to Achieve Low Disease Activity and the Durability of Low Disease Activity? Real-world Results Based on 17 858 European Patients with Axial Spondyloarthritis Initiating a TNF
  https://acrabstracts.org/abstract/what-is-the-impact-of-prior-tnf-inhibitor-treatment-on-the-time-to-achieve-low-disease-activity-and-the-durability-of-low-disease-activity-real-world-results-based-on-17-858-european-patients-with-ax/
  Heberg J, Georgiadis S, Pons M, Loft A, Michelsen B, Linde L, DiGuiseppe D, Rasmussen S, Kazemi M, Macfarlane G, Jones G, Laas K, Vorobjov S, Castrejon I, Rotar Z, Perdan-Pikmajer K, Šenolt L, Baranová J, Glintborg B, Ciurea A, Bernardes M, Valente P, Gudbjornsson B, Gröndal G, Bakland G, Codreanu C, Mogosan C, Iannone F, Caporali R, Karlsson Wallman J, Rantalaiho V, Peltomaa R, Pavelka K, Horak P, Esperança Almeida D, Rodrigues S, Oernbjerg L, Ostergaard M, Hetland M
  
• Predictors of Treatment Response and Continuation in Patients with Psoriatic Arthritis Initiating Secukinumab – Results from the EuroSpA Collaboration
  https://acrabstracts.org/abstract/predictors-of-treatment-response-and-continuation-in-patients-with-psoriatic-arthritis-initiating-secukinumab-results-from-the-eurospa-collaboration/
  Georgiadis S, Ostergaard M, Heberg J, Ahmadzay Z, Michelsen B, Rasmussen S, Kazemi M, Karlsson Wallman J, Olofsson T, Glintborg B, Loft A, Castrejón I, Šenolt L, Nissen M, Moeller B, Garcia J, Barcelos F, Rotar Z, Perdan-Pikmajer K, Codreanu C, Mogosan C, Laas K, Vorobjov S, Gudbjornsson B, Gröndal G, Nordstrom D, Hokkanen A, Mielnik P, Kvien T, Kenar G, Van De Sande M, Hetland M, Oernbjerg L
  
• How fast do JAK-inhibitors, TNF-inhibitors, abatacept and IL-6 inhibitors act in rheumatoid arthritis? An international collaboration of registers of rheumatoid arthritis patients (the "JAK-pot" study)
  https://acrabstracts.org/abstract/how-fast-do-jak-inhibitors-tnf-inhibitors-abatacept-and-il-6-inhibitors-act-in-rheumatoid-arthritis-an-international-collaboration-of-registers-of-rheumatoid-arthritis-patients-the-jak-pot-stu/
  Courvoisier D, Mrad Y, Mongin D, Aymon R, Caporali R, Choquette D, Codreanu C, Coupal L, Huschek D, Hyrich K, Iannone F, Kvien T, Mustak M, Nordstrom D, Trokovic N, Otero-Varela L, Pavelka K, Pombo Suarez M, Provan S, Rodrigues A, Rotar Z, Sidiropoulos P, Strangfeld A, Závada J, Zhao S, Finckh A, Lauper K
  
• Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world data from 1,202 European Patients with Psoriatic Arthritis
  https://acrabstracts.org/abstract/do-smoking-and-obesity-impact-secukinumab-treatment-outcomes-real-world-data-from-1202-european-patients-with-psoriatic-arthritis/
  Ahmadzay Z, Georgiadis S, Ostergaard M, Glintborg B, Møller-Bisgaard S, Pons M, Heberg J, Christiansen S, Rasmussen S, Loft A, Castrejon I, Otero-Varela L, Závada J, Pavelka K, Rutanen J, Kuusalo L, Nissen M, Rotar Z, Perdan-Pikmajer K, Bernardes M, Gudbjornsson B, Gröndal G, van der Horst-Bruinsma I, Laas K, Michelsen B, Codreanu C, DiGuiseppe D, Moeller B, Kenar G, Hetland M, Oernbjerg L
  
• Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Real-World Data from a Nationwide Registry of Rheumatic Diseases
  https://acrabstracts.org/abstract/evaluation-of-the-survival-and-safety-of-biologic-and-targeted-synthetic-dmard-in-patients-with-difficult-to-treat-ra-using-real-world-data-from-a-nationwide-registry-of-rheumatic-diseases/
  Adrián Quevedo-Rodríguez, Lucia Otero-Varela, Fernando Sánchez-Alonso, Yanira Pérez-Vera, Javier Manero-Ruiz, Cristina Campos-Fernández, Sara Manrique-Arija, Paloma Vela-Casasempere, Antonio Mera-Varela, César Díaz, Atusa Movasat, Blanca Garcia-Magallon, Inmaculada Ros-Vilamajó, Carolina Perez-Garcia and Isabel Castrejon, and BIOBADASER working group.
  
• Discontinuation Pattern of Glucocorticoids in Patients with Rheumatoid Arthritis initiating biologics or targeted synthetic DMARDs in routine care
  https://acrabstracts.org/abstract/discontinuation-pattern-of-glucocorticoids-in-patients-with-rheumatoid-arthritis-initiating-biologics-or-targeted-synthetic-dmards-in-routine-care/
  Isabel Castrejón, Lucia Otero-Varela, José María Álvaro-Gracia, Jerusalem Calvo Gutierrez, Cristina Campos-Fernández, Alicia García Dorta, Ana Perez, Dolores Ruiz Montesino and Fernando Sánchez-Alonso, and on behalf of BIOBADASER
  
• Cardiovascular and cancer safety of JAKi compared to TNFi in patients with rheumatoid arthritis: results from a national registry of advanced therapies
  https://acrabstracts.org/abstract/cardiovascular-and-cancer-safety-of-jaki-compared-to-tnfi-in-patients-with-rheumatoid-arthritis-results-from-a-national-registry-of-advanced-therapies/
  Lucia Otero-Varela, Carlos Sanchez-Piedra, Elena Rabadán Rubio, Juan Camilo Sarmiento-Monroy, Chamaida Plasencia-Rodríguez, Diana Sueiro, Olga Martinez, Noemí Busquets Pérez, Mercedes Freire González, Fernando Sánchez-Alonso, José María Álvaro-Gracia and Isabel Castrejon, and BIOBADASER group
  
• One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis. Data of the Spanish BIOBADASER registry
  https://ard.bmj.com/content/83/Suppl_1/1494.1
  Clementina López-Medina* 1 Lucía Otero-Varela 2 Fernando Sánchez-Alonso 2 Vega Jovani 3 Sagrario Bustabad Reyes 4 Sheila Melchor Díaz 5 Yanira Perez-Vera 6 Paula Pretel-Ruiz 7 Francisco Javier Manero Ruiz 8 Antonio Jose Mera-Varela 9 Lourdes Mateo 10 Dolores Ruiz-Montesino 11 María Colazo-Burlato 12 Maria Teresa Pedraz-Penalva 13 Isabel Castrejon 14
  
• Evaluation of the Survival and Safety of Biologic and Targeted Synthetic DMARD in Patients with Difficult-to-Treat RA Using Data from the BIOBADASER 3.0 Registry
  https://ard.bmj.com/content/83/Suppl_1/785.1
  Adrián Quevedo-Rodríguez* 1 Lucía Otero-Varela 2 Fernando Sánchez-Alonso 2 Yanira Perez-Vera 1 Francisco Javier Manero Ruiz 3 Cristina Campos Fernández 4 Sara Manrique-Arija 5 Paloma Vela-Casasempere 6 Antonio Jose Mera-Varela 7 Cesar Diaz-Torne 8 Atusa Movasat 9 Blanca Garcia-Magallon 10 Inmaculada Ros 11 Carolina Perez-Garcia 12 Isabel Castrejon 13
  
• Pattern of use of glucocorticoids in patients with rheumatoid arthritis initiating biologics or targeted synthetic therapies in real life: data from BIOBADASER
  https://ard.bmj.com/content/83/Suppl_1/825.1
  I. Castrejon1,2,3, L. Otero-Varela4, J. M. Alvaro-Gracia5, J. Calvo-Gutiérrez6, C. Campos Fernández7, A. García Dorta8, A. Pérez Gómez9, F. Sánchez-Alonso4
  
• Gender as a key factor of delay in prescribing the first biologic or targeted synthetic drug in patients with rheumatoid arthritis. Data from BIOBADASER 3.0 registry
  https://ard.bmj.com/content/83/Suppl_1/600.1
  Paloma Vela Casasempere* 1 2 3 Lucía Otero-Varela 4 Silvia Gomez-Sabater 2 Rocio Caño-Alameda 2 Cristina Campos Fernández 5 Jerusalem Calvo Gutierrez 6 Yanira Perez-Vera 7 Sara Manrique Arija 8 Sagrario Bustabad 9 Francisco Javier Manero Ruiz 10 Dolores Ruiz-Montesinos 11 Lucía Ruiz 12 Antonio Mera Varela 13 Manuel Moreno 14 Fernando Sánchez-Alonso 4 Isabel Castrejon 15
  
• Gender differences in clinical and prescribing characteristics of biologic and targeted synthetic drugs in naïve patients with rheumatoid arthritis. Data from BIOBADASER 3.0 registry.
  https://ard.bmj.com/content/83/Suppl_1/600.2
  Paloma Vela Casasempere* 1 2 3 Lucía Otero-Varela 4 Silvia Gomez-Sabater 2 Rocio Caño-Alameda 2 Cristina Campos Fernández 5 Jerusalem Calvo Gutierrez 6 Yanira Perez-Vera 7 Sara Manrique Arija 8 Sagrario Bustabad 9 Francisco Javier Manero Ruiz 10 Dolores Ruiz-Montesinos 11 Lucía Ruiz 12 Antonio Mera Varela 13 Manuel Moreno 14 Fernando Sánchez-Alonso 4 Isabel Castrejon 15
  
• The impact of smoking status on one-year secukinumab retention rate in 1,684 patients with psoriatic arthritis: real-world results from the EuroSpA collaboration
  https://ard.bmj.com/content/83/Suppl_1/679.2
  Z. Faizy Ahmadzay1,2, S. Georgiadis3, M. Pons4, M. Lund Hetland5,6, B. Glintborg6,7, S. Møller-Bisgaard8,9, J. Heberg4, S. Nysom Christiansen8, S. Horskjær Rasmussen8, A. G. Loft10,11, I. Castrejon12,13, L. Otero-Varela14, J. Zavada15,16, K. Pavelka15,16, H. Relas17, L. Kuusalo18, B. Moeller19, M. J. Nissen20, Z. Rotar21,22, K. Perdan Pirkmajer22,23, D. Santos Oliveira24, A. R. Cruz-Machado25,26,27, B. Michelsen28,29,30, E. Kristianslund28, B. Gudbjornsson31,32, G. Grondal32,33, K. Laas34, P. He
  
• Infections in patients with rheumatoid arthritis treated with JAK-inhibitors compared to bDMARDs: findings from an international collaboration of registers (the “JAK-POT” study)
  https://ard.bmj.com/content/83/Suppl_1/84
  R. Aymon1, D. Mongin1, B. Gilbert1, R. Guemara1, D. Choquette2, C. Codreanu3, I. Flouri4, D. Huschek5, K. Hyrich6, F. Iannone7, L. Kearsley-Fleet8, T. K. Kvien9, B. F. Leeb10, D. Nordström11, K. Pavelka12, M. Pombo-Suarez13, S. Aarrestad Provan9, A. M. Rodrigues14,15, Z. Rotar16, P. Sidiropoulos17, A. Strangfeld18,19, N. Trokovic11, J. Zavada12, D. S. Courvoisier1, A. Finckh1, K. Lauper1
  
• Predictors of secukinumab treatment response and continuation in axial spondyloarthritis: results from the EuroSpA research collaboration network
  https://ard.bmj.com/content/83/Suppl_1/152
  M. Pons1, S. Georgiadis1, M. Østergaard1,2, Z. Faizy Ahmadzay1, S. Horskjær Rasmussen1, S. Nysom Christiansen1, K. Perdan Pirkmajer3,4, Z. Rotar3,4, D. DI Giuseppe5, J. K. Wallman6, B. Gudbjornsson7,8, Ó. Pálsson6,8, F. Iannone9, B. Glintborg1,2,10, A. G. Loft11,12, K. Pavelka13,14, J. Zavada13,14, M. J. Nissen15, A. Ciurea16, H. Santos17,18, M. H. Fernandes Lourenco19,20, B. Michelsen1,21,22, P. Mielnik23, I. Castrejon24,25, L. Kuusalo26, V. Rantalaiho27, G. J. Macfarlane28, K. Laas29, I. Van d
  
• Tasa de retención y efectividad tras un año de seguimiento en pacientes con artritis psoriásica y espondiloartritis axial tratados con Ixekizumab. Datos de BIOBADASER
  https://static.elsevier.es/reuma/reumacongreso2024b.pdf
  Clementina López-Medina1, Lucía Otero-Varela2, Fernando Sánchez-Alonso2, Vega Jovaní3, Sagrario Bustabad4, Sheila Melchor-Díaz5, Yanira Pérez-Vera6, Paula Pretel-Ruiz7, Javier Manero8, Antonio Mera-Varela9, Lourdes Mateo10, Dolores Ruiz-Montesino11, José Andrés Lorenzo-Martín12, Teresa Pedraz-Penalva13 e Isabel Castrejón14
  
• Pattern of use of glucocorticoids in patients with rheumatoid arthritis initiating biologics or targeted synthetic therapies in real life: data from BIOBADASER
  https://static.elsevier.es/reuma/reumacongreso2024b.pdf
  Isabel Castrejón Fernández1, Lucía Otero-Valera2, José María Álvaro-Gracia1, Jerusalem Calvo3, Cristina Campos4, Alicia García Dorta5, Ana Pérez Gómez6 and Fernando Sánchez-Alonso2
  
• Evaluación de la supervivencia y seguridad de los FAME biológicos y sintéticos dirigidos en pacientes con AR difícil de tratar empleando datos del registro BIOBADASER 3.0
  https://static.elsevier.es/reuma/reumacongreso2024b.pdf
  Adrián Quevedo Rodríguez1, Lucía Otero-Varela2, Fernando Sánchez-Alonso2, Yanira Pérez Vera1 , Javier Manero3, Cristina Campos4, Sara Manrique Arija5, Paloma Vela Casasempere6, Antonio Mera Varela7 , César Díaz Torné8, Atusa Movasat9, Blanca García Magallón10, Inmaculada Ros-Vilamajo11, Carolina Pérez García12 e Isabel Castrejón13
  
• Diferencias de género en las características clínicas y de la prescripción de fármacos biológicos y sintéticos dirigidos en pacientes naïve con artritis reumatoide. Datos del registro BIOBADASER 3.0
  https://static.elsevier.es/reuma/reumacongreso2024b.pdf
  Paloma Vela Casasempere1,2,3, Lucía Otero-Varela4, Silvia Gómez Sabater2, Rocío Caño Alameda2, Cristina Campos5, Jerusalem Calvo-Gutiérrez6, Yanira Pérez-Vera7 , Sara Manrique Arija8, Sagrario Bustabad9, Javier Manero10, Dolores Ruiz Montesinos11, Lucía Ruíz Gutiérrez12, Antonio Mera Varela13, Manuel José Moreno Ramos14, Fernando Sánchez-Alonso4 e Isabel Castrejón15
  
• Seguridad cardiovascular y cáncer de Inhibidores de JAK versus AntiTNF en artritis reumatoide: resultados de BIOBADASER
  https://static.elsevier.es/reuma/reumacongreso2024b.pdf
  Carlos Sanchez-Piedra1,2, Lucía Otero-Varela2, Elena Rabadán3, José Alfredo Gómez Puerta4, Chamaida Plasencia5, Diana Sueiro6, Olga Martínez7, Noemi Busquets8, Mercedes Freire9, Fernando Sánchez-Alonso2, José María Álvaro-Gracia10, e Isabel Castrejón10
  
• Impact of Comorbidities on the First bDMARD Effectiveness and Retention Rate After 2 Years of Follow-up in Patients with Rheumatoid Arthritis. Data from the Spanish Registry BIOBADASER
  https://acrabstracts.org/abstract/impact-of-comorbidities-on-the-first-bdmard-effectiveness-and-retention-rate-after-2-years-of-follow-up-in-patients-with-rheumatoid-arthritis-data-from-the-spanish-registry-biobadaser/
  López Medina C, Calvo J, Otero-Valera L, Escudero Contreras A, Ortega Castro R, Ladehesa Pineda L, Campos C, Bernabeu-Gonzálvez P, Bohorquez C, Garcia Dorta A, Ruiz-Montesinos D, Pombo Suarez M, Ros I, Alonso F, Castrejon I.
  
• Glucocorticoid Use in Rheumatoid Arthritis Patients Initiating Biological or Targeted Synthetic Disease Modifying Anti-rheumatic Drugs (b/tsDMARDs) in Real Life: Data from BIOBADASER
  https://acrabstracts.org/abstract/glucocorticoid-use-in-rheumatoid-arthritis-patients-initiating-biological-or-targeted-synthetic-disease-modifying-anti-rheumatic-drugs-b-tsdmards-in-real-life-data-from-biobadaser/
  Otero-Varela L, Alvaro-Gracia J, Calvo J, Campos C, Garcia Dorta A, Sánchez-Alonso F, Castrejon I
  
• Real-world Persistence of Initial Targeted Therapy Strategy in Monotherapy versus Combination Therapy in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
  https://acrabstracts.org/abstract/real-world-persistence-of-initial-targeted-therapy-strategy-in-monotherapy-versus-combination-therapy-in-patients-with-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis/
  Sánchez-Piedra C, Expósito L, VELA P, Moreno Ramos M, Campos C, Bohorquez C, Calvo J, Plaza Z, Domínguez M, Diaz-Gonzalez J
  
• Insights on the Use of JAK-inhibitors in Patients with Psoriatic Arthritis in an International Collaboration of Registers (the “JAK-pot” Study)
  https://acrabstracts.org/abstract/insights-on-the-use-of-jak-inhibitors-in-patients-with-psoriatic-arthritis-in-an-international-collaboration-of-registers-the-jak-pot-study/
  Aymon R, Mongin D, Leeb B, Mustak-Blagusz M, Závada J, Pavelka K, Nordstrom D, Trokovic N, Iannone F, Codreanu C, Rotar Z, Kvien T, Provan S, Pombo Suarez M, Alonso F, Onen F, Inanc N, Coupal L, Choquette D, Lukina G, Elkayam O, Furer V, Rodrigues A, COURVOISIER D, Finckh A, Nissen M, Lauper K
  
• Use, Safety and Persistence of Biosimilars in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events of Targeted Therapies in Rheumatic Diseases (BIOBADASER)
  https://acrabstracts.org/abstract/use-safety-and-persistence-of-biosimilars-in-adult-patients-diagnosed-with-juvenile-idiopathic-arthritis-results-from-the-spanish-registry-of-adverse-events-of-targeted-therapies-in-rheumatic-diseas/
  Bethencourt J, Otero-Valera L, MANERO J, Perez-Pampin E, Pérez Vera Y, MANRIQUE S, Bustabad Reyes M, Freire González M, Ruiz-Montesinos D, Mateo Soria L, Martín Domenech R, Moreno Ramos M, Alonso F, Castrejon I
  
• Four-year Secukinumab Treatment Outcomes in Axial Spondyloarthritis and Psoriatic Arthritis Patients Treated in Routine Care: Results from the EuroSpA Collaboration
  https://acrabstracts.org/abstract/four-year-secukinumab-treatment-outcomes-in-axial-spondyloarthritis-and-psoriatic-arthritis-patients-treated-in-routine-care-results-from-the-eurospa-collaboration/
  Pons M, Georgiadis S, Faizy Ahmadzay Z, Østergaard M, Glintborg B, Heberg J, Nysom Christiansen S, Horskjær Rasmussen S, Castrejon I, Alonso F, Laas K, Vorobjov S, Khmelinskii N, Zavada J, Ciurea A, Nissen M, Michelsen B, Mielnik P, Loft A, Rotar Z, Perdan Pirkmajer K, Macfarlane G, Jones G, Nordstrom D, Hokkanen A, van der Horst-Bruinsma I, Karlsson Wallman J, Gudbjornsson B, Palsson o, Hetland M, Ørnbjerg L
  
• The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration
  https://acrabstracts.org/abstract/the-impact-of-smoking-status-on-one-year-secukinumab-retention-rate-in-1684-patients-with-psa-real-world-results-from-the-eurospa-collaboration/
  Faizy Ahmadzay Z, Georgiadis S, Pons M, Hetland M, Glintborg B, Heberg J, Nysom Christiansen S, Horskjær Rasmussen S, Loft A, Castrejon I, Otero-Valera L, Zavada J, Pavelka K, Relas H, Kuusalo L, Moeller B, Nissen M, Rotar Z, Perdan Pirkmajer K, Santos Oliveira D, Cruz-Machado A, Michelsen B, Kristianslund E, Gudbjornsson B, Grondal G, Laas K, Hellamand P, Sari I, Di Giuseppe D, Østergaard M, Ørnbjerg L
  
• Comparing Predictors of DAPSA28, DAPSA66/68 and DAS28-CRP Remission at 6 Months in Bio-naive Patients with Psoriatic Arthritis Initiating a TNFi in Clinical Practice – Results from the EuroSpA Collaboration
  https://acrabstracts.org/abstract/comparing-predictors-of-dapsa28-dapsa66-68-and-das28-crp-remission-at-6-months-in-bio-naive-patients-with-psoriatic-arthritis-initiating-a-tnfi-in-clinical-practice-results-from-the-eurospa/
  Georgiadis S, Linde L, Ørnbjerg L, Horskjær Rasmussen S, Askling J, Michelsen B, Di Giuseppe D, Karlsson Wallman J, Glintborg B, Loft A, Bernardes M, Ochôa Matos C, Nordstrom D, Kuusalo L, Moeller B, Nissen M, Gudbjornsson B, Love T, Iannone F, Kvien T, Rotar Z, Castrejon I, Macfarlane G, van de Sande M, Hetland M, Østergaard M
  
• Do long-term patient-reported outcomes improve similarly in psoriatic arthritis and axial spondyloarthritis patients treated with secukinumab? Results from the EuroSpA collaboration
  https://acrabstracts.org/abstract/do-long-term-patient-reported-outcomes-improve-similarly-in-psoriatic-arthritis-and-axial-spondyloarthritis-patients-treated-with-secukinumab-results-from-the-eurospa-collaboration/
  Pons M, Horskjær Rasmussen S, Nysom Christiansen S, Michelsen B, Glintborg B, Gudbjornsson B, Grondal G, Vencovsky J, Loft A, Rotar Z, Perdan Pirkmajer K, Nissen M, Moeller B, Macfarlane G, Jones G, Iannone F, Caporali R, Laas K, Vorobjov S, Di Giuseppe D, Nihan Coskun B, Yagiz B, Provan S, Fagerli K, Castrejon I, Otero-Valera L, van de Sande M, van der Horst-Bruinsma I, Nordstrom D, Kuusalo L, Vieira-Sousa E, Bernardes M, Olofsson T, Baranová J, Hetland M, Østergaard M, Ørnbjerg L.
  
• Impact of the First Three Waves of the Covid-19 Pandemic on Daily Restrictions and Follow-up of Patients with Spondyloarthritis Across Europe
  https://acrabstracts.org/abstract/impact-of-the-first-three-waves-of-the-covid-19-pandemic-on-everyday-restrictions-and-clinical-care-of-patients-with-spondyloarthritis-across-europe-results-from-the-eurospa-collaboration/
  Brigitte Michelsen1, Bente Glintborg2, Kim Lauper3, Bjorn Gudbjornsson4, Lykke Ørnbjerg5, Gerdur Maria Gröndal6, Karin Laas7, Sigrid Vorobjov8, Dan Nordstrom9, Heikki Relas9, Adrian Ciurea10, Burkhard Moeller11, Isabel Castrejon12, Lucia Otero-Valera13, Ziga Rotar14, Katja Perdan Pirkmajer15, Anne Gitte Loft16, Jakub Zavada17, Karel Pavelka18, Eirik Kristianslund19, Tore Kvien20, Marleen van de Sande21, Pasoon Hellamand22, Florenzo Iannone23, Roberto F. Caporali24, Ana Maria Rodrigues25, Maria J
  
• Identificación de los pacientes con mayor probabilidad de retención de golimumab en el largo plazo
  https://static.elsevier.es/reuma/reumacongreso2023.pdf
  Federico Díaz-González1 , Enrique González-Dávila2, Marta Sánchez-Jareño3, Luis Cea-Calvo3, Manuel Pombo-Suárez4, Fernando Sánchez-Alonso5 e Isabel Castrejón6
  
• Characteristics of patients with difficult-to-treat rheumatoid arthritis in real life: data from the BIOBADASER registry
  https://static.elsevier.es/reuma/reumacongreso2023.pdf
  Fernando José Montero Reyes1 , Pablo Rodríguez-Merlos1 , Lucía Otero-Varela2, Francisco Javier Manero Ruiz3, Paloma Vela-Casasempere4, Cristina Campos Fernández5, Sara Manrique Arija6, Carlos Rodríguez-Lozano7 , Olga Martínez González8, Jerusalem Calvo Gutiérrez9, Jose Campos Esteban10, Diana Sueiro Delgado11, Fernando Sánchez-Alonso2 and Isabel Castrejon1
  
• Supervivencia de fármacos bloqueadores de TNFa biosimilares vs originales: resultados del registro BIOBADASER
  https://static.elsevier.es/reuma/reumacongreso2023.pdf
  María Paz Martínez Vidal1 , Cristina Fernández-Carballido1 , Lucía Otero-Varela2, Francisco Javier Manero3, Carlos Rodríguez-Lozano4, Sara Manrique5, Cristina Campos6, Vega Jovaní7 , Lorena Expósito Pérez8, Bonifacio Álvarez Lario9, Javier García-González10, Fernando Sánchez-Alonso2 e Isabel Castrejón11
  
• Monoterapia versus terapia combinada: Datos de supervivencia en vida real en pacientes con artritis reumatoide, artritis psoriásica y espondilitis anquilosante
  https://static.elsevier.es/reuma/reumacongreso2023.pdf
  Carlos Sánchez Piedra1 , Lorena Exposito2, Paloma Vela-Casasempere3, Manuel José Moreno-Ramos4, Cristina Campos5, Cristina Bohorquez6 , Javier Manero7 , Jerusalem Calvo-Gutiérrez8, Carlos Rodríguez-Lozano9, Dolores Ruiz-Montesino10, Noemí Busquets11, Javier García-González12, Isabel Castrejón13, Lucía Otero-Varela14, Fernando Alonso14, Sagrario Bustabad2 y Federico Díaz-González2,15
  
• Impacto de las comorbilidades en la eficacia y en la tasa de retención al primer fármaco biológico en pacientes con Artritis Reumatoide tras dos años de seguimiento. Datos del registro español BIOBADASER
  https://static.elsevier.es/reuma/reumacongreso2023.pdf
  Jerusalem Calvo Gutiérrez1,2,3, Clementina López-Medina1,2,3, Lucía Otero-Varela4, Alejandro Escudero Contreras1,2,3, Rafaela Ortega Castro1,2,3, María Lourdes Ladehesa Pineda1,2,3 Cristina Campos Fernández5, Pilar Bernabéu6, Cristina Bohórquez7, Alicia García Dorta8, Dolores Ruiz-Montesinos9, Manuel Pombo-Suárez10, Inmaculada Ros11, Fernando Sánchez-Alonso4 e Isabel Castrejon12
  
• Patrón de uso y seguridad de los biosimilares en pacientes adultos con diagnóstico de artritis idiopática juvenil. Resultados de BIOBADASER
  https://static.elsevier.es/reuma/reumacongreso2023.pdf
  Juan José Bethencourt Baute1 , Lucía Otero-Varela2, Francisco Javier Manero3, Eva Pérez Pampín4, Carlos Rodríguez-Lozano5, Sara Manrique6, Sagrario Bustabad1, Jesús Carlos Fernández7, Dolores Ruíz Montesinos8, Lourdes Mateo9, Raquel Martín Doménech10, Manuel Moreno-Ramos10, Fernando Sánchez-Alonso2 e Isabel Castrejón12
  
• Characteristics of patients with difficult-to-treat rheumatoid arthritis in real life: data from the BIOBADASER registry
  http://scientific.sparx-ip.net/archiveeular/?c=a&view=1&searchfor=biobadaser&item=2023AB0202
  P. Rodríguez-Merlos1, L. Otero-Varela2, F. Montero1, F. J. Manero Ruiz3, P. Vela-Casasempere4, C. Campos Fernández5, S. Manrique Arija6, C. Rodríguez-Lozano7, O. Martínez González8, J. Calvo Gutierrez9, J. Campos Esteban10, D. Sueiro Delgado11, F. Sánchez-Alonso2, I. Castrejon1
  
• Survival of biosimilar anti-TNFa blockers compared to originator molecules in rheumatology: results from the BIOBADASER cohort
  http://scientific.sparx-ip.net/archiveeular/?c=a&view=1&searchfor=biobadaser&item=2023POS0638
  M. P. Martínez-Vidal1, C. Fernández-Carballido1, L. Otero-Varela2, F. J. Manero Ruiz3, C. Rodríguez-Lozano4, S. Manrique Arija5, C. Campos Fernández6, V. Jovani7, L. Expósito8, M. Colazo9, J. García-González10, F. Sánchez-Alonso2, I. Castrejon11
  
• Use of biosimilar therapies in adult patients diagnosed with juvenile idiopathic arthritis: results from the Spanish registry of adverse events with biologic therapies (BIOBADASER)
  http://scientific.sparx-ip.net/archiveeular/?c=a&view=1&searchfor=biobadaser&item=2023AB1423
  J. J. Bethencourt Baute1, L. Otero-Varela2, F. J. Manero Ruiz3, E. Perez-Pampín4, C. Rodríguez-Lozano5, S. Manrique Arija6, S. Bustabad7, C. Fernández-López8, D. Ruiz Montesinos9, L. Mateo10, R. Martín-Domenech11, M. Moreno12, F. Sánchez-Alonso2, I. Catrejón13
  
• Safety of biosimilars therapies for the treatment of juvenile idiopathic arthritis: results from the Spanish registry of adverse events with biologic therapies (BIOBADASER)
  http://scientific.sparx-ip.net/archiveeular/?c=a&view=1&searchfor=biobadaser&item=2023POS0281
  J. J. Bethencourt Baute1, L. Otero-Varela2, F. J. Manero Ruiz3, E. Perez-Pampín4, C. Rodríguez-Lozano5, S. Manrique Arija6, S. Bustabad1, C. Fernández-López7, D. Ruiz Montesinos8, L. Mateo9, R. Martín-Domenech10, M. Moreno11, F. Sánchez-Alonso2, I. Catrejón12
  
• Impact of comorbidities on the first bDMARD effectiveness and retention rate after 2 years of follow-up in patients with Rheumatoid Arthritis. Data from the Spanish registry BIOBADASER
  http://scientific.sparx-ip.net/archiveeular/?c=a&view=1&searchfor=biobadaser&item=2023POS1073
  J. Calvo Gutierrez1,2,3, C. López-Medina1,2,3, L. Otero-Varela4, A. Escudero Contreras1,2,3, R. Ortega Castro1,2,3, M. L. Ladehesa Pineda1,2,3, C. Campos Fernández5, P. Bernabéu6, C. Bohórquez7, A. García Dorta8, D. Ruiz-Montesinos9, M. Pombo-Suarez10, I. Ros11, F. Sánchez-Alonso4, I. Castrejon12
  
• Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with JAK-inhibitors compared to bDMARDS: data from an international collaboration of registries (the “JAK-POT” study)
  http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=jak%20pot&view=1&item=2023OP0219
  R. Aymon1, D. Mongin1, S. A. Bergstra2, D. Choquette3, C. Codreanu4, R. L. Cordtz5, D. C. Diederik6, L. Dreyer5, O. Elkayam7, D. Huschek8, K. Hyrich9, F. Iannone10, N. Inanc11, L. Kearsley-Fleet9, T. K. Kvien12, B. Leeb13, G. Lukina14, D. Nordström15, F. Onen16, K. Pavelka17, M. Pombo-Suarez18, S. Aarrestad Provan12, A. M. Rodrigues19, Z. Rotar20, A. Strangfeld8, P. Verschueren6, J. Zavada17, D. Courvoisier1, A. Finckh1, K. Lauper1
  
• Sex differences in patient-reported outcomes in axial spondyloarthritis patients treated with tumor necrosis factor inhibitors: results from a multinational observational cohort study
  http://scientific.sparx-ip.net/archiveeular/?searchfor=biobadaser&c=a&view=1&item=2023POS0249
  P. Hellamand1, M. G. H. Van de Sande1, M. T. Nurmohamed1, R. Van Vollenhoven1, R. Hollick1, O. Rotariu1, Z. Rotar1, K. Pirkmajer1, D. Nordström1, A. M. Hokkanen1, B. Michelsen1, T. K. Kvien1, B. Glintborg1, A. G. Loft1, K. Pavelka1, J. Zavada1, I. Castrejon1, L. Otero-Varela1, B. Gudbjornsson1, O. Palsson1, M. Østergaard1, M. L. Hetland1, J. K. Wallman1, D. DI Giuseppe1, A. Ciurea1, M. J. Nissen1, T. Demirci Yildirim1, F. Onen1, C. Codreanu1, C. Mogosan1, M. J. Santos1, E. Vieira-Sousa1, F. Iann
  
• Retención a 8 años del tratamiento con golimumab en pacientes con espondiloartritis axial y factores asociados
  https://static.elsevier.es/reuma/reumacongreso2022.pdf
  M. Pombo-Suárez1 , D. Seoane-Mato2, L. Cea-Calvo3, F. Díaz-González4, F. Sánchez-Alonso2, M. Sánchez-Jareño3, M. Martínez-Morillo5, I. Ros Vilamajó6, C. Rodríguez-Lozano7 e I. Castrejón8
  
• Golimumab tras la discontinuación de fármacos con mecanismo de acción distinto a la inhibición del TNF en pacientes con enfermedades reumáticas inflamatorias: tasa de retención a cuatro años
  https://static.elsevier.es/reuma/reumacongreso2022.pdf
  M. Pombo-Suárez1 , D. Seoane-Mato2, L. Cea-Calvo3, F. Díaz-González4, F. Sánchez-Alonso2, M. Sánchez-Jareño3, F.J. Manero Ruiz5, P. Pretel6, V. Jovani7 e I. Castrejón8
  
• Factores asociados con la retención del tratamiento con golimumab en pacientes con artritis psoriásica. Seguimiento hasta 8 años
  https://static.elsevier.es/reuma/reumacongreso2022.pdf
  M. Pombo-Suárez1 , D. Seoane-Mato2, L. Cea-Calvo3, F. Díaz-González4, F. Sánchez-Alonso2, M. Sánchez-Jareño3, C. Campos Fernández5, C. Díaz-Torné6, R. Martín Doménech7 e I. Castrejón8
  
• Risk of cancer after biologic and targeted synthetic DMARDs initiation in patients with rheumatic diseases and a history of prior malignancy: data from the BIOBADASER registry
  https://static.elsevier.es/reuma/reumacongreso2022.pdf
  J. Molina Collada1,2, F. Alonso3, C. Bohórquez4, C. Díaz Torné5, C. Pérez García6, J.M. Blanco Madrigal7 , P. Vela8 and I. Castrejón1,2
  
• Factores asociados a la retención del tratamiento con golimumab en artritis reumatoide en el registro de BIOBADASER, con 7 años de seguimiento
  https://static.elsevier.es/reuma/reumacongreso2022.pdf
  M. Pombo-Suárez1 , D. Seoane-Mato2, L. Cea-Calvo3, F. Díaz-González4, F. Sánchez-Alonso2, M. Sánchez-Jareño3, B. García-Magallón5, O. Martínez González6 e I. Castrejón7
  
• Cancer in patients with rheumatic diseases exposed to different biologic and targeted synthetic DMARDs in realworld clinical practice: data from a multicenter register
  https://static.elsevier.es/reuma/reumacongreso2022.pdf
  I. Castrejón Fernández1 , J. Molina Collada1,2, C. Pérez García3, P. Vela-Casasempere4, C. Díaz Torne5, C. Bohórquez6 , J.M. Blanco Madrigal7 and F. Sánchez-Alonso8
  
• Golimumab after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases: four-year retention rate in the Spanish BIOBADASER registry
  https://ard.bmj.com/content/81/Suppl_1/1504.2
  M. Pombo-Suarez1 , D. Seoane-Mato2 , F. Diaz-Gonzalez3 , F. Sánchez-Alonso2 , L. Cea-Calvo4 , M. Sánchez-Jareño4 , V. Jovani5 , P. Pretel6 , F. J. Manero Ruiz7 , I. Castrejon8 on behalf of BIOBADASER Investigators
  
• Factors associated with long-term retention of treatment with Golimumab in a large cohort of patients with rheumatic diseases, with up to 8 years of follow-up
  https://ard.bmj.com/content/81/Suppl_1/773
  M. Pombo-Suarez1 , D. Seoane-Mato2 , L. Cea-Calvo3 , F. Diaz-Gonzalez4 , F. Sánchez-Alonso2 , M. Sánchez-Jareño3 , F. J. Manero Ruiz5 , L. Ruiz6 , V. Jovani7 , I. Castrejon8 on behalf of BIOBADASER investigators. 1
  
• Higher 5-year survival of Certolizumab Pegol in young women with axial spondyloarthritis. BIOBADASER data
  https://ard.bmj.com/content/81/Suppl_1/769.1
  M. Moreno1 , C. Sánchez-Piedra2 , V. Jovani3 , R. Cáliz Cáliz4 , Y. PerezVera5 , V. Emperiale6 , F. Sanchez-Alonso2 , M. Pombo7 , M. Llop Vilaltella1 , J. Calvet1 on behalf of BIOBADASER project working group.
  
• Cancer in patients with rheumatic diseases exposed to different biologic and targeted synthetic DMARDs in real-world clinical practice: data from a multicenter register
  https://ard.bmj.com/content/81/Suppl_1/1063
  I. Castrejon1,2, J. Molina Collada1,2, C. Perez-Garcia3 , P. Vela-Casasempere4 , C. Diaz-Torne5 , C. Bohórquez6 , J. M. Blanco7 , F. Sánchez-Alonso8 on behalf of BIOBADASER.
  
• Risk of cancer after biologic and targeted synthetic DMARDs initiation in patients with rheumatic diseases and a history of prior malignancy: data from the BIOBADASER registry
  https://ard.bmj.com/content/81/Suppl_1/88.2
  J. Molina Collada1,2, F. Sánchez-Alonso3 , C. Bohórquez4 , C. Diaz-Torne5 , C. Perez-Garcia6 , J. M. Blanco7 , P. Vela-Casasempere8 , I. Castrejon1,2.
  
• Can single imputation techniques for BASDAI components reliably calculate the composite score in axial spondyloarthritis patients?
  https://ard.bmj.com/content/81/Suppl_1/212
  S. Georgiadis1 , M. Riek2 , C. Polysopoulos2 , A. Scherer2 , D. DI Giuseppe3 , G. T. Jones4 , M. L. Hetland1,5, M.  Østergaard1,5, S. H. Rasmussen1 , J. K. Wallman6 , B. Glintborg1 , A. G. Loft7,8, K. Pavelka9 , J. Zavada9 , M. Birlik10, A. Yazici11, B. Michelsen1,12,13, E. Kristianslund12, A. Ciurea14, M. J. Nissen15, A. M. Rodrigues16,17, M. J. Santos18, G. Macfarlane19, A. M. Hokkanen20, H. Relas21, C. Codreanu22, C. Mogosan22, Z. Rotar23, M. Tomsic23, B. Gudbjornsson24, A. J. Geirsson25, P. 
  
• Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from thirteen countries in the EUROSPA Research Collaboration Network
  https://ard.bmj.com/content/annrheumdis/81/Suppl_1/259.1.full.pdf
  P. Hellamand1 , M. G. H. Van de Sande2 , L. Midtbøll Ørnbjerg3 , T. Klausch4 , N. Trokovic5 , T. Sokka-Isler6 , M. J. Santos7 , E. Vieira-Sousa8 , A. G. Loft9,10, B. Glintborg11, M.  Østergaard3,12, U. Lindström13, J. K. Wallman14, B. Michelsen3,15,16, B. Moeller17, R. Micheroli18, C. Codreanu19, C. Mogosan19, K. Laas20, Z. Rotar21,22, K. M. Fagerli23, M. Tomsic21,22, I. Castrejon24, M. Pombo-Suarez25, B. Gudbjornsson26, T. Love27, K. Pavelka28,29, J. Zavada28,29, G. Kenar30, H. Yarkan-Tu sal30,
  
• Sex differences in effectiveness of first-line tumor necrosis factor inhibitors in axial spondyloarthritis; results from fifteen countries in the EUROSPA Research Collaboration Network
  https://ard.bmj.com/content/81/Suppl_1/13
  P. Hellamand1 , M. G. H. Van de Sande2 , L. Midtbøll Ørnbjerg3 , T. Klausch4 , M. Nurmohamed5 , R. Van Vollenhoven6,7, D. Nordström8 , A. M. Hokkanen9 , M. J. Santos10, E. Vieira-Sousa11, A. G. Loft12,13, B. Glintborg3 , M.  Østergaard3,14, U. Lindström15, J. K. Wallman16, B. Michelsen3,17,18, A. Ciurea19, M. J. Nissen20, C. Codreanu21, C. Mogosan21, G. Macfarlane22, G. T. Jones22, K. Laas23, Z. Rotar24,25, M. Tomsic24,25, I. Castrejon26, M. Pombo-Suarez27, B. Gudbjornsson28,29, A. J. Geirsson30
  
• Treatment discontinuation due to adverse events as an overall measure of tolerance and safety of jak-inhibitors: an international collaboration of registries of rheumatoid arthritis patients (the “JAKPOT” study)
  https://ard.bmj.com/content/81/Suppl_1/177
  E. Nham1 , R. Aymon1 , D. Mongin1 , S. A. Bergstra2 , D. Choquette3 , C. Codreanu4 , O. Elkayam5 , K. Hyrich6,7, F. Iannone8 , N. Inanc9 , L. KearsleyFleet6 , E. Kristianslund10, T. K. Kvien10, B. Leeb11,12, G. Lukina13, D. Nordström14, K. Pavelka15, M. Pombo-Suarez16, Z. Rotar17, M. J. Santos18, D. Courvoisier1 , K. Lauper1,6, A. Finckh1
  
• Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic and Targeted Synthetic DMARDs in Real World Clinical Practice: Data from BIOBADASER
  https://acrabstracts.org/abstract/cancer-risk-in-patients-with-rheumatic-diseases-exposed-to-different-biologic-and-targeted-synthetic-dmards-in-real-world-clinical-practice-data-from-biobadaser/
  Castrejon I, Molina J, Perez-Garcia C, Vela-Casampere P, Diaz-Torne C, Bohorquez C, Blanco-Madrigal J, Sanchez-Alonso F
  
• Cancer Risk with Biologic and Targeted Synthetic DMARDs in Patients with Rheumatic Diseases and Previous Malignancy: Results from the BIOBADASER Register
  https://acrabstracts.org/abstract/cancer-risk-with-biologic-and-targeted-synthetic-dmards-in-patients-with-rheumatic-diseases-and-previous-malignancy-results-from-the-biobadaser-register/
  Molina J, Sanchez-Alonso F, Bohorquez C, Diaz-Torne C, Perez-Garcia C, Blanco-Madrigal J, Vela-Casampere P, Älvaro-Gracia J, Castrejon I
  
• Evaluation of Treatment Discontinuation Due to Adverse Events, and the Effect of Cardiovascular Risk Factors or Type of JAK-inhibitors: An International Collaboration of Registries of Rheumatoid Arthritis Patients (the ‘JAK-pot‘ Study)
  https://acrabstracts.org/abstract/evaluation-of-treatment-discontinuation-due-to-adverse-events-and-the-effect-of-cardiovascular-risk-factors-or-type-of-jak-inhibitors-an-international-collaboration-of-registries-of-rheumatoid-arthr/
  Kim Lauper1, Romain Aymon2, Denis Mongin2, Sytske Anne Bergstra3, Denis Choquette4, Catalin Codreanu5, Ori Elkayam6, Kimme Hyrich7, Florenzo Iannone8, Nevsun Inanc9, Lianne Kearsley-Fleet10, Tore K. kvien11, Eirik Kristianslund12, Burkhard Leeb13, Galina Lukina14, Dan Nordstrom15, Karel Pavelka16, Manuel Pombo-Suarez17, Ziga Rotar18, Maria José Santos19, Delphine Courvoisier20 and Axel Finckh21
  
• Tratamiento con golimumab en pacientes que discontinuaron biológicos con mecanismo de acción distinto a los anti TNF-alfa o nuevos FAME selectivos en el registro BIOBADASER
  https://static.elsevier.es/reuma/reumacongreso2021.pdf
  M. Pombo-Suárez1 , C. Sánchez-Piedra2, M.D. Ruiz Montesino3, C. Díaz-Torné4, V. Jovaní5, M.J. Arteaga6, L. Cea-Calvo6 e I. Castrejón7
  
• Retención y seguridad de secukinumab en la práctica clínica habitual: registro español BIOBADASER
  https://static.elsevier.es/reuma/reumacongreso2021.pdf
  M.J. Moreno-Martínez1 , C. Sánchez-Piedra2, C. Pérez-García3, L. Linares1 , J. Campos4, C. Campos5, R. Cáliz-Caliz6, J. Calvo7 , Y. Pérez-Vera8, A. Movasat9, O. Martínez-González10, J.M. Blanco-Madrigal11, M.J. Moreno-Ramos12, F. Sánchez-Alonso2, C. Sastré13 e I. Castrejón14
  
• Perfil clínico de mujeres embarazadas diagnosticadas con patologías reumáticas inflamatorias y seguridad de la terapia biológica: datos de práctica clínica del registro BIOBADASER
  https://static.elsevier.es/reuma/reumacongreso2021.pdf
  C. Membrive Jiménez1 , C. Sánchez-Piedra2, O. Martínez-González3, B. García-Magallon4, F. Sánchez-Alonso2, R. Caliz1 e I. Castrejón5
  
• Mayor supervivencia a 5 años de certolizumab pegol en mujeres adultas de menos de 45 años con espondiloartritis axial. Datos de BIOBADASER
  https://static.elsevier.es/reuma/reumacongreso2021.pdf
  M. Moreno Martínez-Losa, C. Sánchez-Piedra2, R. Martín-Domenech3, R. Caliz4, B. García-Magallón5, C. Campos6, F. Sánchez-Alonso2, I. Castrejón7 , M. Llop1 y J. Calvet1
  
• Efectividad de secukinumab en pacientes con artritis psoriásica en la práctica clínica habitual: registro español BIOBADASER
  https://static.elsevier.es/reuma/reumacongreso2021.pdf
  M.J. Moreno-Ramos1 , C. Sánchez-Piedra2, O. Martínez-González3, J.M. Blanco-Madrigal4, C. Pérez-García5, L. Linares1 , J. Campos6, C. Campos7 , R. Cáliz-Caliz8, J. Calvo9, Y. Pérez-Vera10, E. Rabadán11, M.J. Moreno-Martínez12, F. Sánchez-Alonso2, C. Sastré13 e I. Castrejón14
  
• Factores asociados a la suspensión por remisión en pacientes en tratamiento con terapia biológica y sintéticos dirigidos: resultados de práctica clínica real
  https://static.elsevier.es/reuma/reumacongreso2021.pdf
  M. Valero Expósito1 , C. Sánchez-Piedra2, M. Freire3, M. Colazo4, N. Busquets5, E. Meriño6, F. Sánchez-Alonso2 e I. Castrejón7
  
• Epidemiologic profile and channeling to treatment in rheumatoid arthritis patients treated with abatacept over the last 5 years: data from the Spanish register BIOBADASER 3.0
  https://static.elsevier.es/reuma/reumacongreso2021.pdf
  S. de la Cruz Rodríguez García, C. Sánchez-Piedra2, J. Manero3, C. Rodríguez-Lozano4, S. Manrique5, B. García-Magallón6, C. Campos7 , R. Caliz8, C. Díaz-Torne9, P. Vela-Casasempere10, F. Sánchez-Alonso2e I. Castrejón11
  
• Efectividad de secukinumab en pacientes con espondiloartritis axial en la práctica clínica habitual: registro español BIOBADASER
  https://static.elsevier.es/reuma/reumacongreso2021.pdf
  M.J. Moreno-Ramos1 , C. Sánchez-Piedra2, R. Caliz-Caliz3, J. Calvo4, Y. Pérez-Vera5, L. Montaño6, O. Martínez-González7 , J. María Blanco-Madrigal8, C. Pérez-García9, J. Campos10, C. Campos11, L. Linares1 , M. José Moreno-Martínez12, F. Sánchez-Alonso2, C. Sastré13 e I. Castrejón14
  
• Secular trends in baseline characteristics, treatment retention and response rates in 27189 bio-naïve axial spondyloarthritis patients initiating TNFi – results from the EUROSPA collaboration
  https://ard.bmj.com/content/80/Suppl_1/217
  L. Midtbøll Ørnbjerg1 , S. N. Christiansen1 , S. H. Rasmussen1 , A. G. Loft2,3, U. Lindström4 , J. Zavada5 , F. Iannone6 , F. Onen7 , M. J. Nissen8 , B. Michelsen1,9, M. J. Santos10, G. Macfarlane11, D. Nordström12, M. Pombo-Suarez13, C. Codreanu14, M. Tomsic15, I. Van der Horst-Bruinsma16, B. Gudbjornsson17, J. Askling18, B. Glintborg1,3, K. Pavelka5 , E. Gremese19, N. Akkoc20, A. Ciurea21, E. Kristianslund9 , A. Barcelos22, G. T. Jones23, A. M. Hokkanen24, C. SánchezPiedra25, R. Ionescu14, Z. 
  
• Secular trends in baseline characteristics, treatment retention and response rates in 17453 bionaïve psoriatic arthritis patients initiating TNFi – results from the EUROSPA collaboration
  https://ard.bmj.com/content/80/Suppl_1/131.2
  S. N. Christiansen1 , L. Midtbøll Ørnbjerg1 , S. H. Rasmussen1 , A. G. Loft2,3, J. K. Wallman4 , F. Iannone5 , B. Michelsen1,6, M. J. Nissen7 , J. Zavada8 , M. J. Santos9 , M. Pombo-Suarez10, K. Eklund11, M. Tomsic12, B. Gudbjornsson13, I. Sari14, C. Codreanu15, D. DI Giuseppe16, B. Glintborg1,3, M. Sebastiani17, K. M. Fagerli6 , B. Moeller18, K. Pavelka8 , A. Barcelos19, C. Sánchez-Piedra20, H. Relas11, Z. Rotar12, T. Love13, S. Akar21, R. Ionescu15, G. Macfarlane22, M. G. H. Van de Sande23, M.
  
• Epidemiologic profile and channeling to treatment in Rheumatoid Arthritis patients treated with Abatacept over the last 5 years: data from the Spanish register BIOBADASER 3.0
  https://ard.bmj.com/content/80/Suppl_1/542.1
  S. C. Rodriguez-García1 , C. Sánchez-Piedra2 , R. Castellanos-Moreira3 , D. RuizMontesinos4 , M. Pombo5 , F. Sánchez-Alonso2 , J. J. Gómez-Reino6 on behalf of the BIOBADASER Working group
  
• Safety profile of jak-inhibitors versus TNF-inhibitors in real-world clinical practice: data from a multicenter register
  https://ard.bmj.com/content/80/Suppl_1/68.1
  B. Hernández-Cruz1 , C. Sánchez-Piedra2 , M. Freire González3 , N. Busquets4 , J. García-González5 , M. Moreno6 , J. M. Blanco7 , S. Manrique Arija8 , E. PerezPampín9 , F. Sánchez-Alonso2 , I. Castrejon10on behalf of BIOBADASER.
  
• Heterogeneity in adverse event assessment between countries participating in an international collaboration of registries of Rheumatoid Arthritis patients using Janus Kinase inhibitors (the JAK-POT study)
  https://ard.bmj.com/content/80/Suppl_1/256
  K. Lauper1 , D. Mongin1 , S. A. Bergstra2 , D. Choquette3 , C. Codreanu4 , D. De Cock5 , L. Dreyer6 , O. Elkayam7 , K. Hyrich8 , F. Iannone9 , N. Inanc10, E. Kristianslund11, T. K. Kvien11, B. Leeb12, G. Lukina13, D. Nordström14, K. Pavelka15, M. Pombo-Suarez16, Z. Rotar17, M. J. Santos18,19, A. Strangfeld20, D. Courvoisier1 , A. Finckh1 on behalf of Epidemiology and registry working group
  
• Effectiveness of Cycling JAKi Compared to Switching to bDMARD in Patients Who Failed a First JAKi in an International Collaboration of Registries of Rheumatoid Arthritis Patients (the JAK-pot Study)
  https://acrabstracts.org/abstract/effectiveness-of-cycling-jaki-compared-to-switching-to-bdmard-in-patients-who-failed-a-first-jaki-in-an-international-collaboration-of-registries-of-rheumatoid-arthritis-patients-the-jak-pot-study/
  Manuel Pombo-Suarez1, Carlos Sanchez-Piedra2, Juan J Gomez-Reino3, Kim Lauper4, Nevsun Inanc5, Anja Strangfeld6, Doreen Huschek7, Karel Pavelka8, Eirik Kristianslund9, Tore Kvien10, Ziga Rotar11, Dan Nordström12, Denis Choquette13, Ori Elkayam14, Burkhard Leeb15, Maria José Santos16, Kimme Hyrich17, Lianne Kearsley-Fleet18, Catalin Codreanu19, Denis Monguin20, Delphine Courvoisier20 and Axel Finckh21,
  
• Factores asociados a la persistencia del tratamiento con golimumab en el registro BIOBADASER con hasta 7 años de seguimiento
  https://static.elsevier.es/congresos/pdf/111/reuma2020_2.pdf
  M. Pombo-Suárez1 , C. Sánchez-Piedra2, L. Cea-Calvo3, M.J. Moreno-Ramos4, J. Manero5, C. Rodríguez-Lozano6, B. García-Magallón7 , M.J. Arteaga3, F. Sánchez-Alonso2 y J.J. Gómez-Reino
  
• Factores asociados a la persistencia del tratamiento con golimumab en pacientes con artritis psoriásica: 7 años de seguimiento en el registro BIOBADASER
  https://static.elsevier.es/congresos/pdf/111/reuma2020_2.pdf
  M. Pombo-Suárez1 , C. Sánchez-Piedra2, L. Cea-Calvo3, E. Alonso4, M. Freire5, O. Martínez-González6, D. Ruiz Montesinos7 , P. Palazón-Riquelme3, F. Sánchez-Alonso2 y J.J. Gómez-Reino1
  
• Factores asociados a la persistencia del tratamiento con golimumab en artritis reumatoide: 6 años de seguimiento en el registro BIOBADASER
  https://static.elsevier.es/congresos/pdf/111/reuma2020_2.pdf
  M. Pombo-Suárez1 , C. Sánchez-Piedra2, L. Cea-Calvo3, C. Pérez-García4, A. García-Dorta5, I. Ros6, Y. Pérez Vera7 , S. Fernández3, F. Sánchez-Alonso2 y J.J. Gómez-Reino1
  
• Factores asociados a la persistencia del tratamiento con golimumab en pacientes con espondiloartritis axial: 7 años de seguimiento en el registro BIOBADASER
  https://static.elsevier.es/congresos/pdf/111/reuma2020_2.pdf
  M. Pombo-Suárez1 , C. Sánchez-Piedra2 , L. Cea-Calvo3 , R. Martín-Doménech4 , J.C. Fernández López5 , C. Díaz-Torne6 , V. Jovani Casano7 , L. Feo-Lucas3 , F. Sánchez-Alonso2 y J.J. Gómez-Reino1
  
• The combined vaccination scheme against streptococcus pneumoniae is effective in rheumatoid arthritis patients treated with DMARD: data from BIOBADASER 3.0
  https://static.elsevier.es/congresos/pdf/111/reuma2020_2.pdf
  S. de la Cruz Rodríguez García1 , C. Sánchez-Piedra2, R. Castellanos-Moreira3, J. Manero4, Y. Pérez-Vera5, S.Manrique6, C. Campos7 , R. Caliz8, M.V. Hernández3, C. Díaz-Torné9, P. Vela-Casasempere10, B. García-Magallón11 F. Sánchez-Alonso2, L. Carmona12 and J.J. Gómez-Reino13
  
• Safety and persistence of Ustekinumab in patients with Psoriatic Arthritis in BIOBADASER
  https://ard.bmj.com/content/79/Suppl_1/1672.2
  N. Busquets-Pérez1 , C. Sánchez-Piedra2 , P. Vela-Casasempere3 , M. FreireGonzalez4 , C. Bohórquez5 , L. Expósito6 , B. Magallon7 , F. Manero8 , J. Del Pino Montes9 , C. Diaz Torne10, R. Martin Domenech11, M. Pascual12, F. SánchezAlonso2
  
• The combined vaccination scheme against streptococcus pneumoniae is effective in Rheumatoid Arthritis patients treated with DMARD: data from BIOBADASER 3.0
  https://ard.bmj.com/content/annrheumdis/79/Suppl_1/706.2.full.pdf
  S. C. Rodriguez-García1 , C. Sánchez-Piedra2 , R. Castellanos-Moreira3 , D. RuizMontesinos4 , V. Hernandez3 , M. Pombo5 , F. Sánchez-Alonso2 , L. Carmona6 , J. J. Gómez-Reino5 on behalf of BIOBADASER Study group
  
• Factors associated with persistence of Golimumab treatment in the BIOBADASER registry, up to 7 years of follow-up
  https://ard.bmj.com/content/79/Suppl_1/733.2
  M. Pombo1 , C. Sánchez-Piedra2 , L. Cea-Calvo3 , S. Manrique Arija4 , B. GarciaMagallon5 , C. Campos Fernández6 , I. Notario7 , F. Diaz-Gonzalez8 , J. J. GomezReino1
  
• Drug retention rates and treatment outcomes in 1860 axial spondyloarthritis patients treated with Secukinumab in routine clinical practice in 13 European countries in the EUROSPA Research Collaboration Network
  http://scientific.sparx-ip.net/archiveeular/?c=a&view=1&searchfor=sanchez-piedra&item=2020THU0398
  B. Michelsen1, U. Lindström1, C. Codreanu1, A. Ciurea1, J. Zavada1, A. G. Loft1, M. Pombo-Suarez1, F. Onen1, T. K. Kvien1, Z. Rotar1, M. J. Santos1, F. Iannone1, A. M. Hokkanen1, B. Gudbjornsson1, J. Askling1, R. Ionescu1, M. Nissen1, K. Pavelka1, C. Sánchez-Piedra1, S. Akar1, J. Sexton1, M. Tomsic1, H. Santos1, M. Sebastiani1, J. Osterlund1, A. J. Geirsson1, G. T. Jones1, I. Van der Horst-Bruinsma1, S. Georgiadis1, C. H. Brahe1, L. Midtbøll Ørnbjerg1, M. L. Hetland1, M. ?stergaard1
  
• Comparative effectiveness of jak-inhibitors, TNF-inhibitors, Abatacept and IL-6 inhibitors in an international collaboration of registers of Rheumatoid Arthritis patients (the “jak-pot” study)
  https://ard.bmj.com/content/79/Suppl_1/146
  K. Lauper1 , D. Mongin1 , S. A. Bergstra2 , D. Choquette3 , C. Codreanu4 , D. De Cock5 , L. Dreyer6 , O. Elkayam7 , K. Hyrich8 , F. Iannone9 , N. Inanc10, E. Kristianslund11, T. K. Kvien11, B. Leeb12, G. Lukina13, D. Nordström14, K. Pavelka15, M. Pombo-Suarez16, Z. Rotar17, M. J. Santos18, A. Strangfeld19, D. Courvoisier1 , A. Finckh1 .
  
• Infection and Malignancy Outcomes in Patients with RA Treated with Abatacept: Results from a Multinational Surveillance Study
  https://acrabstracts.org/abstract/infection-and-malignancy-outcomes-in-patients-with-ra-treated-with-abatacept-results-from-a-multinational-surveillance-study/
  Dominique A, Hetland M, Finckh A, Gottenberg J, Iannone F, Caporali R, Nordstrom D, Hernandez M, Sanchez-Piedra C, Sanchez-Alonso F, Pavelka K, Krístková Z, Simon T
  
• The Impact of the Combined Vaccination Scheme Against Streptococcus Pneumoniae on the Incidence of Related Infections in Patients with Rheumatoid Arthritis Treated with Biologic or Targeted Synthetic DMARD: Data from BIOBADASER 3.0
  https://acrabstracts.org/abstract/the-impact-of-the-combined-vaccination-scheme-against-streptococcus-pneumoniae-on-the-incidence-of-related-infections-in-patients-with-rheumatoid-arthritis-treated-with-biologic-or-targeted-synthetic/
  Sebastian Rodriguez-Garcia1, Carlos Sanchez-Piedra2, Raul Castellanos-Moreira3, Dolores Ruiz-Montesinos4, Victoria Hernandez5, Manuel Pombo-Suarez6, Fernando Sanchez-Alonso2, Loreto Carmona7 and JJ Gómez-Reino8,
  
• Impacto de la edad al inicio del tratamiento biológico en la aparición de eventos adversos: Datos del registro BIOBADASER 3.0 
  https://www.reumatologiaclinica.org/es-vol-15-num-sc-sumario-X1699258X19X44058
  C.P. Vela Casasempere1,2, C. Sánchez-Piedra3, C. Pérez-García4, S. Manrique5, M.C. Castro-Villegas6, B. García-Magallon7, J. Manero8, S. Gómez2, R. Caño2, F. Sánchez-Alonso3, F. Díaz-González3y J.J. Gómez-Reino9
  
• Factores asociados a la persistencia del tratamiento con golimumab en el registro BIOBADASER, con hasta 6 años de seguimiento
  https://www.reumatologiaclinica.org/es-vol-15-num-sc-sumario-X1699258X19X44058
  M.E. Pombo Suárez1, C. Sánchez-Piedra2, E. Cuende3, R. Martín-Domenech4, J. del Pino5, C. Campos6, J. Manero7, B. García-Magallon8, F. Sánchez-Alonso2, F. Díaz9, M.J. Arteaga10, L. Cea-Calvo10 y J.J. Gómez-Reino1
  
• Impact of age on the appearance of adverse events at the beginning of biological treatment: data from the BIOBADASER 3.0 registry
  http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=biobadaser&view=2&item=2019SAT0168
  Paloma Vela-Casasempere1,2,3, Carlos Sánchez-Piedra4, Carolina Perez-Garcia5, Sara Manrique Arija6, María del Carmen Castro Villegas7, Blanca Garcia-Magallon8, Javier Manero9, Silvia Gomez-Sabater2, Rocio Caño-Alameda2, Fernando Sánchez-Alonso4, le Federico Diaz-Gonzaz4,10, Jesus GomeJuan z-Reino10
  
• Changing pattern of the use of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
  http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=sanchez-piedra&view=1&item=2019SAT0159
  Carlos Sánchez-Piedra1, Águeda Prior-Español2, Mercedes Freire González3, María Colazo4, Dolores Ruiz-Montesinos5, Yanira Perez-Vera6, Ana Ortiz7, Sagrario Bustabad8, Paloma Vela-Casasempere9, Marta Rojas-Giménez10, Fernando Sánchez-Alonso1, Federico Diaz-Gonzalez1, Juan Jesus Gomez-Reino11, BIOBADASER group
  
• Factors associated to persistence of treatment with Golimumab in the BIOBADASER registry, with up to 6 years of follow-up
  http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=biobadaser&view=2&item=2019SAT0158
  Manuel Pombo1, Carlos Sánchez-Piedra2, Eduardo Cuende3, Raquel Martín-Domenech4, Javier del Pino5, Cristina Campos Fernández6, Javier Manero7, Blanca Garcia-Magallon8, Fernando Sánchez-Alonso2, Federico Diaz-Gonzalez9, María J. Arteaga10, Luis Cea-Calvo10, J Juan1, Gómez-Reino
  
• Survival of JAJ inhibitors: real-world data from the BIOBADASER III registry
  http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=biobadaser&view=2&item=2019FRI0146
  Valentina Emperiale1,2, Carlos Sánchez-Piedra1, Eduardo Cuende2, Paloma Vela-Casasempere3, María del Carmen Castro Villegas4, Sara Manrique Arija5, Cristina Campos Fernández6, Javier del Pino7, Manuel Pombo8, Fernando Sánchez-Alonso1, Juan Jesus Gomez-Reino8
  
• Effectiveness of biologic therapy on disease activity in Ankylosing Spondylitis: a BIOBADASER III observational study
  http://scientific.sparx-ip.net/archiveeular/?c=a&searchfor=biobadaser&view=2&item=2019FRI0389
  Valentina Emperiale, Carlos Sánchez-Piedra, Cristina Bohórquez, María Colazo, Carlos Fernández-López, Noemí Busquets, Inmaculada Ros, J. M. Blanco, Manuel Moreno, Jose Campos Esteban, Carlos Rodríguez-Escalera, Fernando Sánchez-Alonso, Juan Jesus Gomez-Reino11
  
• High Baseline Patient’s Compared with Evaluator’s Global Assessment Is Associated with Lower Retention and Remission Rates of First TNF Inhibitor in Psoriatic Arthritis Patients – Data from the EuroSpA Research Collaboration Network
  https://acrabstracts.org/abstract/high-baseline-patients-compared-with-evaluators-global-assessment-is-associated-with-lower-retention-and-remission-rates-of-first-tnf-inhibitor-in-psoriatic-arthritis-patients-data/
  Brigitte Michelsen1, Lykke Midtbøll Ørnbjerg 2, Herman Mann 3, Tore Kvien 4, Michael J. Nissen 5, Maria José Santos 6, Dan Nordström 7, Lennart Jacobsson 8, Ziga Rotar 9, Bjorn Gudbjornsson 10, Süleyman Serdar Koca 11, Catalin Codreanu 12, Manuel Pombo-Suarez 13, Irene van der Horst-Bruinsma 14, Anne Gitte Loft 15, Karel Pavelka 3, Eirik Kristianslund 16, Burkhard Moeller 17, Elsa Vieira-Sousa 18, Anna Mari Hokkanen 19, Ulf Lindström 20, Matija Tomsic 21, Thorvardur J Love 22, Abdurrahman Tufan
  
• Predictors of DAPSA28 Remission at 6 Months in Bio-Naive Patients with Psoriatic Arthritis Starting a TNF Inhibitor in Clinical Practice– Results from the EuroSpA Collaboration
  https://acrabstracts.org/abstract/predictors-of-dapsa28-remission-at-6-months-in-bio-naive-patients-with-psoriatic-arthritis-starting-a-tnf-inhibitor-in-clinical-practice-results-from-the-eurospa-collaboration/
  Lykke Midtbøll Ørnbjerg1, Stylianos Georgiadis 2, Lennart Jacobsson 3, Anne Gitte Loft 4, Florenzo Iannone 5, Burkhard Moeller 6, Joe Sexton 7, Herman Mann 8, Maria José Santos 9, Manuel Pombo-Suarez 10, Kari K. Eklund 11, Matija Tomsic 12, Bjorn Gudbjornsson 13, Sükran Erten 14, Catalin Codreanu 15, Irene van der Horst-Bruinsma 16, Johan Wallman 17, Marco Sebastiani 18, Michael J. Nissen 19, Eirik Kristianslund 20, Karel Pavelka 8, Elsa Vieira-Sousa 21, Carlos Sánchez-Piedra 22, Nina Trokovic 2
  
• Heterogeneity in the Pattern of Use of JAK-inhibitors Between Countries Participating in an International Collaboration of Registers of Rheumatoid Arthritis Patients (the JAK-pot Study)
  https://acrabstracts.org/abstract/heterogeneity-in-the-pattern-of-use-of-jak-inhibitors-between-countries-participating-in-an-international-collaboration-of-registers-of-rheumatoid-arthritis-patients-the-jak-pot-study/
  Kim Lauper1, Denis Mongin 2, Sytske Anne Bergstra 3, Denis Choquette 4, Catalin Codreanu 5, Ori Elkayam 6, Kimme Hyrich 7, Florenzo Iannone 8, Eirik Kristianslund 9, Tore Kvien 10, Burkhard Leeb 11, Galina Lukina 12, Dan Nordström 13, Fatos Onen 14, Karel Pavelka 15, Manuel Pombo-Suarez 16, Ziga Rotar 17, Maria José Santos 18, Anja Strangfeld 19, Delphine Courvoisier 20 and Axel Finckh 20
  
• Changes in the Initial Usage Pattern of Biologic Disease-modifying Antirheumatic Drugs in Rheumatic Diseases During the past Twelve Years: A Real-world Setting Analysis
  https://acrabstracts.org/abstract/changes-in-the-initial-usage-pattern-of-biologic-disease-modifying-antirheumatic-drugs-in-rheumatic-diseases-during-the-past-twelve-years-a-real-world-setting-analysis/
  Carlos Sánchez-Piedra1, María Colazo 2, Rosa Roselló 3, Cristina Campos 4, P. Vela 5, Cristina Bohorquez 6, Carolina Pérez-García 7, Manuel Pombo-Suarez 8, Carlos Fernández-López 9, Dolores Ruiz-Montesinos 10, Fernando Alonso 11, Federico Diaz-Gonzalez 12 and Juan Jesús Gómez-Reino 13
  
• Factores asociados con la persistencia del tratamiento con golimumab en pacientes con enfermedades inflamatorias articulares. Análisis del registro BIOBADASER
  https://www.reumatologiaclinica.org/es-vol-14-num-sc-sumario-X1699258X18X43274
  M.V. Hernández Miguel1, R. Morlá1, S. Rodríguez-García1, C. Sánchez-Piedra2, F. Sánchez-Alonso2, E. Pérez-Pampín3, A. Ortiz4, M.D. Ruiz Montesinos5, C. Campos6, S. Manrique7, M. Medrano San Idelfonso8, V. Jovaní Casano9, L. Mateo10, C. Díaz-Torné11, B. García-Magallón12, C. Hernández Santana13, R. Cáliz Cáliz14, R. Martín Doménech15, L. Expósito16, L. Barrio Nogal17, E. Collantes18, M. Freire19, J. del Pino20, E. Rubio21, J.A. Gómez-Puerta1, R. Sanmartí1, M.J. Arteaga22 y J.J. Gómez-Reino3
  
• Factors associated to persistence on Golimumab in patients with inflammatory arthritis of the BIOBADASER registry
  https://ard.bmj.com/content/77/Suppl_2/1755.3
  M.V. Hernández1 , S. Rodriguez1 , R. Morlà1 , C. Sánchez-Piedra2 , F. SánchezAlonso2 , F.J. Manero3 , B. García-Magallón4 , E. Pérez-Pampín5 , C. RodríguezLozano6 , M.D. Ruiz7 , A. Ortiz8 , C. Díaz-Torné9 , L. Mateo10, J.A. Gómez-Puerta1 , R. Sanmartí1 , L. Cea-Calvo11, J.J. Gómez-Reino5 , on behalf of BIOBADASER Study Group
  
• Use of biological therapies in adult patients diagnosed with juvenile idiopathic arthritis: results from BIOBADASER, the Spanish registry of adverse events with biologic therapies
  https://ard.bmj.com/content/77/Suppl_2/491.2
  J.J. Bethencourt Baute1 , C. Sanchez-Piedra2 , F. Sanchez-Alonso2 , D. RuizMontesinos3 , J. Manero4 , C. Rodriguez-Lozano5 , E. Perez-Pampin6 , A. Ortiz7 , S. Manrique8 , M.V. Hernandez9 , C. Campos10, A. Sellas11, A. Sifuentes12, J. García-González13, J.J. Gomez-Reino14, F. Díaz-Gonzalez15, S. BustabadReyes16, on behalf of BIOBADASER STUDY GROUP
  
• Commonalities and differences in data collection across European spondyloarthritis registries
  https://congress2017.eular.org/myUploadData/files/2017_ARD_full_abstracts.pdf
  M.L. Hetland 1, M. Østergaard 1, J. Askling 2, C. Gabay 3, D. Nordstrom 4, O. FitzGerald 5, M. Hernández Miguel 6, M. Santos 7, Z. Rotar 8, H. Mann 9, F. Iannone 10, M.J. Nissen 3, E. Hauge 1, J. Gomez-Reino 11, F. Díaz-González 12, M. Tomsic 8, K. Pavelka 9, F. O’Shea 5, C. Sullivan 5, M. van de Sande 13, I.E. van der Horst-Bruinsma 13, G.J. Macfarlane 14, G.T. Jones 14, B. Gudbjørnsson 15, T.K. Kvien 16 on behalf of EuroSpA Study Group
  
• Use of Biological Therapies in Adult Patients Diagnosed with Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)
  https://acrabstracts.org/abstract/use-of-biological-therapies-in-adult-patients-diagnosed-with-juvenile-idiopathic-arthritis-results-from-the-spanish-registry-of-adverse-events-with-biologic-therapies-biobadaser/
  Sánchez-Piedra C, Rosello R, Manero J, Hernández MV, Sánchez-Alonso F, Cuende E, García Magallon B, Ortiz Garcia AM, Diaz-Torné C, Freire M, Vela P, Menor Almagro R, Prior A, Díaz-González F, Gomez-Reino JJ, Bustabad S
  
• Safety of Biologic Therapies for the Treatment of Juvenile Idiopathic Arthritis: Results from the Spanish Registry of Adverse Events with Biologic Therapies (BIOBADASER)
  ttps://acrabstracts.org/abstract/safety-of-biologic-therapies-for-the-treatment-of-juvenile-idiopathic-arthritis-results-from-the-spanish-registry-of-adverse-events-with-biologic-therapies-biobadaser/
  Bethencourt Baute JJ, Sánchez-Piedra C, Expósito Pérez L, Hernández MV, Manero J, Rosello R, Sánchez-Alonso F, Ruiz-Montesinos D, Perez Pampín E, Rodriguez-Lozano C, Campos Fernandez C, Fernández-Carballido C, Martín-Domenech R, Del Pino-Montes J, Freire M, Díaz-González F, Gomez-Reino JJ, Bustabad S
  
• Predictors of discontinuation of Biologic DMARD therapy due to remission in patients with Rheumatoid Arthritis in a National Registry (BIOBADASER)
  
  Jose A. Gómez-Puerta, M Victoria Hernandez, Fernando Alonso, Kazuki Yoshida, Raimon Sanmartí, Dan H. Solomon, Juan J. Gómez-Reino
  
• Demyelinating Diseases, Optic Neuritis, and Multiple Sclerosis in rheumatic diseases treated with anti-TNF therapy
  Ann Rheum Dis 2009;68(Suppl3):83
  Fernández-Espartero MC, Pérez-Zafrilla B, Roselló R, Mera A, Silva L, Calvo-Alén J, Ruiz T, Noguera R, Maymo J, Boquet D, Salaberri J, Carmona L.
  
• Treatment Survival and Safety of anti-TNF alpha Treatments in Elderly Patients.
  Ann Rheum Dis 2009;68(Suppl3):164
  Busquets N, Pérez-Zafrilla B, Descalzo M, Cerdà D, Ortiz V, Ponce A, Surís X.
  
• Paciente en tratamiento con antiTNF. Registro Español de Terapias Biológicas en Enfermedades Reumáticas. Biobadaser
  V Congreso de enfermedades infecciosas SEINORTE 2009
  Beatriz Pérez-Zafrilla
  
• Terapias Biológicas e infección: Magnitud del problema.
  XVII Reunión Científica SOCARE 2009
  Beatriz Pérez-Zafrilla
  
• Is the exposure to TNF antagonists a risk factor for Cancer in Rheumatoid Arthritis?
  Arthritis Rheum 2008,59;9(Supplement):1266
  Abásolo L, Carmona L, Gomez-Reino JJ
  
• Is The Incidence Risk Of Cancer Constant Through Time In Rheumatoid Arthritis Patients Exposed to Biologics?
  Arthritis Rheum 2008,59;9(Supplement):1661
  Abásolo L, Carmona L, Gomez-Reino JJ
  
• Is Psoriasis a complication of Anti-TNF Treatment?
  Arthritis Rheum 2008,59;9(Supplement):1662
  Pérez-Zafrilla B, García de Yebenes MJ, Dauden E, Gomez-Reino JJ, Carmona L, BIOBADASER Study Group
  
• Morbilidad cardiovascular y terapia anti-TNF
  XIV Simposio Internacional de Inflamación y Enfermedades Reumáticas 2008
  Beatriz Pérez-Zafrilla
  
• What is a relevant adverse event?. Disagreements in the communication of adverse events: analysis with the BIOBADASER research team.
  Ann Rheum Dis 2008;67(Suppl II):575
  Perez-Zafrilla B, García J, Granados P, Hernández V, Joven B, Manero J, Ortiz A, Perez Pampín E, Roselló R, Sellas A, Ureña I, Carmona L
  
• Rates of herpes zoster in patients with rheumatoid arthritis and treatment with TNF antagonists. Incidence rate in BIOBADASER cohort in comparison with EMECAR cohort.
  Ann Rheum Dis 2008;67(Suppl II):327
  Perez-Zafrilla B, García Doval I, Carmona L
  
• Administration Related Reactions with anti-TNFs are varied, can appear at any time of the treatment and up to 14 days after administration.
  Ann Rheum Dis 2007;66(Suppl II):184
  Perez-Zafrilla B, Carmona L, Descalzo M, Gomez-Reino J, BIOBADASER Study Group.
  
• Incidencia, Cronología y Etiología de las Infecciones Osteoarticulares en Pacientes Reumatológicos Tratados con Terapias Biológicas. (Póster)
  XII Reunión de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. 9-11 mayo 2007. La Coruña.
  MJ Pérez-Sola, MA Descalzo, M González-Padilla, A. Doblas, JM Cisneros, J Torre-Cisneros y grupo BIOBADASER.
  
• Incidencia, Distribución y Etiología de las Complicaciones Infecciosas en Pacientes Reumatológicos Tratados con Terapias Biológicas. (Póster)
  XII Reunión de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. 9-11 mayo 2007. La Coruña.
  MJ Pérez-Sola, MA Descalzo, JJ Castón, M González-Padilla, JM Cisneros, J Torre-Cisneros y grupo BIOBADASER.
  
• Incidencia, Cronología y Etiología de las Neumonías en Pacientes Reumatológicos Tratados con Terapias Biológicas. (Póster)
  XII Reunión de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. 9-11 mayo 2007. La Coruña.
  MJ Pérez-Sola, MA Descalzo, JJ Castón, M González-Padilla, JM Cisneros, J Torre-Cisneros y grupo BIOBADASER.
  
• Incidencia, distribución y etiología de las complicaciones infecciosas en pacientes reumatológicos tratados con antagonistas del factor de necrosis tumoral alfa". (Póster)
  VIII Congreso de la Sociedad Andaluza de Enfermedades Infecciosas. 14-16 diciembre 2006. Roquetas de Mar. Almería.
  MJ Pérez Sola, JM Cisneros Herreros, J Torre-Cisneros, grupo BIOBADASER.
  
• Mortality from Cardiovascular Causes is Reduced in Rheumatoid Arthritis Patients Treated With TNF Antagonist. (Póster).
  2006 Annual Scientific Meeting of the American College of Rheumatology. Washington D.C., 10-15 noviembre 2006.
  Carmona L, Gómez-Reino J, Pérez-Pampín E, Descalzo MA, BIOBADASER Study Group.
  
• Assessment of The Impact of Compliance with Recommendations to Avoid Active Tuberculosis in Patients Treated With TNF Antagonist. (Póster).
  2006 Annual Scientific Meeting of the American College of Rheumatology. Washington D.C., 10-15 noviembre 2006.
  Carmona L, Gómez-Reino J, Descalzo MA, BIOBADASER Study Group.
  
• Neumonía intersticial inflamatoria en pacientes con artritis reumatoide en tratamiento con antagonistas del TNF-alfa. Tasa de incidencia y mortalidad en BIOBADASER y comparación con la cohorte EMECAR. (póster).
  XXXI Congreso Nacional de la Sociedad Española de Reumatología, Las Palmas de Gran Canaria, 18-20 de Mayo de 2005.
  R García de Vicuña, AM Ortiz García, L Carmona Ortells, M Ibáñez Barceló, I Castrejón Fernández, A Laffon Roca y Grupo de estudio BIOBADASER.
  
• There is no Clear Increase of Cancer in Patients Receiving Biologicals for Rheumatic Diseases (póster).
  ACR/AHRP Annual Scientific Meeting, 16-21 octubre 2004, San Antonio, Texas.
  L Carmona, BIOBADASER Scientific Committee and Study Group.
  
• Spanish registry of biological treatment in rheumatic diseses.
  Third Workshop on European Biologics Registries (Berlín, 22 de enero de 2004).
  L. Carmona Ortells.
  
• Seguridad con las terapias anti-TNF: ¿Existen diferencias entre la artritis reumatoide y la enfermedad de Crohn?.
  Reunión de la Sociedad Española de Reumatología con la Asociación Española de Gastroenterología. Marbella, 8 de febrero de 2003.
  Carmona, L
  
• An Active Surveillance of Rheumatoid Arthritis Patients Treated with Tumor Necrosis Factor Inhibitors Shows Significant Increase in the Risk for Tuberculosis [Abstract nº 1416, póster].
  2002 Annual Scientific Meeting of the American College of Rheumatology. New Orleans, 24-29 octubre 2002.
  JJ Gómez-Reino, L Carmona, E Martin Mola, Comité Científico BIOBADASER.
  
• Spanish experience with a registry of adverse events in biological therapy.
  Annual European Congress of Rheumatology Eular 2002. 12 de junio de 2002, Estocolmo. (Abstract n:0420 AB0156).
  Comité Científico BIOBADASER.
  
• Biobadaser: Registro de acontecimientos adversos de terapias biológicas en enfermedades reumáticas (póster).
  II Jornadas de Farmacovigilancia. 25 de mayo 2001, Zaragoza.
  L.Carmona, Comité Científico de BIOBADASER.
  
• Inflammatory interstitial lung disease in rheumatoid arthritis patiens treated with biologic treatment. Incidence and mortality rates compared with patients non receiving biologics. [Abstract nº 2100 póster].
  Meeting of the European League against Rheumatism. Viena, 11 de junio de 2005.
  R García de Vicuña, A Ortiz, L Carmona.
  
• Embarazos en pacientes en tratamiento con terapia anti-TNF.
  IX Congreso SORCOM. Madrid, 15 y 16 de diciembre de 2005.
  B Joven, AJ García-González, T Ruiz, E Moreno, L Cebrián, M Valero, C Pérez, F Martínez, L Carmona, I Mateo, grupo BIOBADASER.
  
• Pregnancy in Women Receiving Anti-TNF-Alpha Therapy. Experience in Spain. [póster].
  2005 Annual Scientific Meeting of the American College of Rheumatology. San Diego, 14-17 noviembre 2005.
  BE Joven, AJ Garcia-Gonzalez, T Ruiz, E Moreno, L Cebrian, M Valero, C Pérez, F Martínez, L Carmona, I Mateo, G BIOBADASER.
  
• Do Biologics Work Better for Spondylarthritis than for Rheumatoid Arthritis? The BIOBADASER Experience. [comunicación oral].
  2005 Annual Scientific Meeting of the American College of Rheumatology. San Diego, 14-17 noviembre 2005.
  L Carmona, JJ Gómez-Reino, BIOBADASER Study Group.